Ultragenyx CEO talks the company’s path to profitability in developing drugs for rare diseases

ShareShare Article via FacebookShare Article via TwitterShare Article via LinkedInShare Article via Email Harsh Kumar, Piper Sandler senior research analyst, joins ‘TechCheck’ to discuss Kumar’s hesitations around Micron’s stock, what would lessen his concerns around Micron and whether the Chips Act is baked in to his rating on Micron. 06:23 Wed, Mar 30 202211:34 AM…

CNBC’s Jeniece Pettitt gets the scoop on Samsung’s Family Hub Refrigerator at CES with Justin Reinke, Samsung’s Product Director.

ShareShare Article via FacebookShare Article via TwitterShare Article via LinkedInShare Article via Email Closing Bell: Overtime Stacy Rasgon, Bernstein Research chip analyst, joins ‘Closing Bell: Overtime’ to discuss semiconductor stocks. 04:32 Fri, Sep 9 20225:20 PM EDT

ShareShare Article via FacebookShare Article via TwitterShare Article via LinkedInShare Article via Email Bitcoin ETFs begin trading, with several of them already in the red. CNBC’s Bob Pisani joins us with Bitwise Asset Management CIO Matt Hogan to discuss the sector. The Investment Committee also debates their top picks in the sector.

ShareShare Article via FacebookShare Article via TwitterShare Article via LinkedInShare Article via Email Prescription drugs have weird names. But so do planets in the Star Wars universe. We asked CNBC staffers whether they could tell the difference. 02:04 Fri, Apr 10 20159:30 AM EDT

ShareShare Article via FacebookShare Article via TwitterShare Article via LinkedInShare Article via Email Mohamed El-Erian, Allianz chief economic advisor and president of Queens’ College, Cambridge, joins ‘Squawk Box’ to discuss the latest market trends, what to expect from today’s December CPI data, the impact on the Fed’s rate path decision, and more.